The importance of HDAC inhibition as a viable anti-tumor strategy is underlined by the fact that currently four HDACis are approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer [6]. This evidence concerns the gene HDAC9 and neoplasm.